| Title: |
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. |
| Authors: |
Patel, B; Kirkwood, AA; Dey, A; Marks, DI; McMillan, AK; Menne, TF; Micklewright, L; Patrick, P; Purnell, S; Rowntree, CJ; Smith, P; Fielding, AK |
| Source: |
Leukemia (2016) |
| Publication Year: |
2016 |
| Collection: |
University College London: UCL Discovery |
| Description: |
Safety and efficacy data on pegylated asparaginase (PEG-ASP) in adult acute lymphoblastic leukaemia (ALL) induction regimens are limited. The UK National Cancer Research Institute UKALL14 trial NCT01085617 prospectively evaluated the tolerability of 1000 IU/m(2) PEG-ASP administered on days 4 and 18 as part of a five-drug induction regimen in adults aged 25-65 years with de novo ALL. Median age was 46.5 years. Sixteen of the 90 patients (median age 56 years) suffered treatment-related mortality during initial induction therapy. Eight of the 16 died of sepsis in combination with hepatotoxicity. Age and Philadelphia (Ph) status were independent variables predicting induction death >40 versus ⩽40 years, odds ratio (OR) 18.5 (2.02-169.0), P=0.01; Ph- versus Ph+ disease, OR 13.60 (3.52-52.36), P40 years. It proved extremely toxic in patients with Ph+ ALL, possibly owing to interaction with imatinib.Leukemia advance online publication, 9 September 2016; doi:10.1038/leu.2016.219. |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| Relation: |
https://discovery.ucl.ac.uk/id/eprint/1508952/1/leu2016219a.pdf; https://discovery.ucl.ac.uk/id/eprint/1508952/ |
| Availability: |
https://discovery.ucl.ac.uk/id/eprint/1508952/1/leu2016219a.pdf; https://discovery.ucl.ac.uk/id/eprint/1508952/ |
| Rights: |
open |
| Accession Number: |
edsbas.5F5C2D4 |
| Database: |
BASE |